Atrial natriuretic peptide (ANP) as an additive to peritoneal dialysis solutions
AssigneesBaxter International Inc., Miles G. Johnston
InventorsChi J. Chen, Ty R. Shockley, Miles G. Johnston
Life of this patent
Estimating the term…
Abstract
The present invention provides a peritoneal dialysis solution that contains atrial natriuretic peptide (ANP), a derivative of ANP, an analogue of ANP, a substance that binds ANP to clearance receptors or a substance that promotes ANP synthesis, which results in an increased net ultrafiltration and increased sodium clearance experienced in peritoneal dialysis patients.
Claims20
An improved peritoneal dialysis solution comprising.
- an osmotic agent;
- and
- atrial natriuretic peptide (ANP).
A peritoneal dialysis solution comprising from about:
- 120to 150 (mEq/L) sodium;
- 0 to 110 (mEq/L) chloride;
- 0 to 45 (mEq/L) lactate;
- 0 to 45 (mEq/L) bicarbonate;
- 0 to 4.0 (mEq/L) calcium;
- 0 to 4.0 (mEq/L) magnesium;
- an osmotic agent;
- and
- atrial natriuretic peptide (ANP).
A method of improving a peritoneal dialysis solution, the method comprising the following step:
- adding atrial natriuretic peptide (ANP) and an osmotic agent to the peritoneal dialysis solution.
A method of performing peritoneal dialysis on a patient which results in an increased net ultrafiltration, the method comprising:
- administering to the patient a peritoneal dialysis solution comprising a component selected from the group consisting of atrial natriuretic peptide (ANP), a substance that binds to ANP clearance receptors and a substance that promotes the synthesis of ANP.
An improved peritoneal dialysis solution comprising a component selected from the group consisting of:
- an osmotic agent;
- and
- atrial natriuretic peptide (ANP), a substance that binds to ANP clearance receptors and a promoter of ANP synthesis.
Dependencies are inferred from the claim text.